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Obesity is an epidemic problem in the world and is associated with several health problems, including diabetes, cardiovascular
disease, respiratory failure, muscle weakness, and cancer. The precise molecular mechanisms by which obesity induces these health
problems are not yet clear. To better understand the pathomechanisms of human disease, good animal models are essential. In this
paper, we will analyze animal models of obesity and their use in the research of obesity-associated human health conditions and
diseases such as diabetes, cancer, and obstructive sleep apnea syndrome.
1.Introduction
Obesity, deﬁned as a body mass index (BMI) >30kg/m2,i sa
signiﬁcant health problem [1]. Obesity has reached epidemic
proportions globally, and the World Health Organization
estimates that there are more than 1 billion overweight
adults, of which at least 300 million are obese [2]. Societal
changes and the worldwide nutrition transition have driven
the obesity epidemic over recent decades. Economic growth
as well as modernization, urbanization and globalization
of food markets are some of the elements that have con-
tributedtotheobesityepidemic.Signiﬁcantshiftstowardless
physically demanding work have been observed worldwide.
Decreased physical activity has also been associated with
increasing opportunities to use automated transport, have
technology in the home, and engage in more passive leisure
pursuits [2].
Obesity is associated with premature death through
increasing the risk of many chronic diseases, including
type 2 diabetes, cardiovascular disease, and certain cancers
(Figure 1)[ 3, 4]. In addition, obesity is associated with
respiratory diﬃculties, chronic musculoskeletal problems,
lumbago, skin problems, and infertility (Figure 1)[ 4].
Most of the evidence proposing obesity-associated health
problems has been obtained from epidemiological analyses
of human subjects; the precise molecular mechanisms of
obesity-associated health problems have not yet been deter-
mined. In this paper, we will summarize reports associated
with obesity-related pathology using animal models and
also propose further demand for animal research models to
address the worldwide obesity epidemic.
2. AnimalModels of Obesity
There are many rodent and nonrodent models of obesity. We
introduce several widely used important animal models of
obesity in this section.
2.1. Rodent Models
2.1.1. Monogenic Mouse Obesity
Lethal Yellow Mutant Mouse (Ay). Among the several com-
monly existing obese mice currently used in research, the
agouti mutation mouse was ﬁrst reported more than century
ago. In 1992, the agouti protein was cloned by Bultman et
al., and agouti became the ﬁrst obesity gene characterized
at the molecular level [5]. Agouti is a pigment control gene
transiently expressed in follicular melanocytes to induce the
production of red/yellow pheomelanin pigment and inhibit
black/brownpigment[6–8].Thelethalyellowmutantmouse
(Ay) is one of ﬁve dominant agouti mutations and has been
found to be an excellent mouse model of obesity [5]. The
Ay mutation is characterized by the deletion of 120–170kb
genomic DNA, resulting in ubiquitous agouti expression due2 Journal of Biomedicine and Biotechnology
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Figure 1: Obesity-associated complications. Obesity is associated
with various health conditions in humans.
to loss of the tissue-speciﬁc control promoter element [9–
11]. Ay mice exhibit several phenotypes such as a yellow coat
color, mature-onset obesity, type-II diabetes, hyperleptine-
mia, increased linear growth, higher tumor susceptibility,
and infertility [5]. Transgenic mice expressing ubiquitous
agouti exhibited yellow coat color, obesity, hyperinsulinemia,
and hyperglycemia similar to Ay mouse [12], revealing the
molecular mechanism of agouti in mouse phenotype. Mice
with adipose tissue-speciﬁc agouti overexpression exhibit
an overgrowth of adipose tissue without alteration of food
intake, suggesting that increased fat in this model is due
to changes in energy metabolism [13]. The adipose tissue
agouti overexpression model could be relevant to human
obesity because agouti gene expression is found in human
adipose tissue [14, 15] and is increased in the adipose tissue
of type 2 diabetic subjects [16]. Likely the ectopic expression
of agouti in mice pancreas stimulated the release of insulin
by pancreatic β-cells, which may further enhance agouti-
stimulated lipogenesis [17]. Transgenic Agouti expression in
skin did not induce obesity, suggesting that the obesogenic
role of agouti is tissue dependent [18].
Leptin Signaling Defects in Mice: ob/ob and db/db Mouse
Models. In 1949, researchers from the Jackson Laboratory
discovered obese mice by chance [19]. Responsible mutation
gene is named as obese (ob) gene. The ob/ob mutation
is recessive, and neonatal mutant mice are normal when
compared to unaﬀected control littermates. Mutant mice,
however, gain weight rapidly throughout their lives, even-
tually reaching a weight that is three times that of control
mice. The phenotype is clear, but identiﬁcation of the gene
responsible for the obese phenotype took nearly 50 years
[20]. In 1994, Zhang et al. identiﬁed the mutation in the
leptin gene as responsible for ob mutation by positional
cloning [20]. Leptin is a gene expressed abundantly in the
adipose tissue. Characterization of this mutation revealed
a single base pair deletion in the leptin coding region
that results in a frame shift and a premature stop codon
[20]. The leptin protein plays an important role in appetite
control. Therefore, ob/ob mice exhibit uncontrollable food
intake, obesity, type 2 diabetes, and insulin resistance with
hyperinsulinemia.
The db/db mouse was identiﬁed initially in 1966 by
researchers in the Jackson Laboratory as an obese mouse
[21].Thedb(standsfor“diabetes”)mutationisanautosomal
recessivetraitthatencodesforaG-to-Tpointmutationinthe
leptin receptor gene, resulting in defective leptin signaling
[22, 23]. Impaired leptin signaling in the hypothalamus
leads to persistent hyperphagia and obesity, with consequent
hyperleptinemia, insulin resistance, and increased insulin
levels[22,23].At1monthofage,db/dbmicearelarger/obese
when compared to control (heterozygous) littermates, and
db/db mice present increased fat deposition in the inguinal
and axillary regions. db/db mice also develop frank hyper-
glycemia by 8 weeks of age. Consequently, these mice are
widely used as a model for the study of type 2 diabetes
[22, 23].
2.1.2. Polygenic Mouse Obesity. Although monogenic models
provide important information on the biology of obesity,
human obesity is most likely mediated by multiple genes.
Therefore, polygenic models could be much more relevant
to human obesity.
New Zealand Obese (NZO) Mouse. The NZO strain is a
polygenic mouse model of obesity that exhibits type 2
diabetes only in males. NZO mice increase their body
weight rapidly during the ﬁrst 2 months of life because of
hyperphagia that may be associated with leptin resistance,
although they have genetically normal leptin and leptin
receptors. Among polygenic mouse models of obesity, NZO
mice exhibit the most severe phenotype, with fat depots
accounting for more than 40% of total body weight at
6 months of age [24]. Additionally, NZO mice exhibit
decreasedexerciseactivitywhencompared tocontrolor even
ob/ob mice [25]. This information suggests that like human
obesity, obesity in NZO mice is due to a combination of
hyperphagia, reduced energy expenditure, and insuﬃcient
physical activity.
Tsumura Suzuki Obese Diabetes (TSOD) Mouse. Through
the selection of obese and urine sugar positive colonies from
the ddY strain of mice, Tsumura and Suzuki established
two inbred strains. The TSOD strain develops obesity with
diabetes, whereas the Tsumara Suzuki nonobese (TSNO)
strain does not become obese [26]. Male TSOD mice exhibit
polygenic obesity with hyperglycemia and hyperinsulinemia
[26, 27]. Although the mean values of fed blood glucose con-
centrations in TSOD mice are increased with age (232mg/dl
at 13 weeks, 269mg/dl at 16 weeks, and 346mg/dl at 24
weeks), severe diabetes does not develop because TSOD mice
display increased β-cell mass and maintain insulin secretionJournal of Biomedicine and Biotechnology 3
to control blood glucose [26]. Older TSOD mice display
similar lesion as diabetic nephropathy and neuropathy [28].
M16 Mouse. The M16 mouse, an outbred mouse model of
early-onset polygenic obesity, was developed through long-
term selection for 3- to 6-week weight gain in an ICR
background [29]. M16 mice exhibit hyperphagia, hyperin-
sulinemia, and hyperleptinemia compared to ICR controls.
M16 males and females were found to be moderately
hyperglycemiccomparedtoICRcontrols,with56%and22%
higher fasted plasma glucose levels, respectively, at 8 weeks of
age [29].
Kuo Kondo (KK) Mouse. The KK mouse is a polygenic
model of obesity that also exhibits type 2 diabetes. The
KK mouse was developed in Japan with selective inbreeding
for large body size [30]. KK mice display hyperphagia,
hyperinsulinemia, and insulin resistance and show moderate
obesity by 2 months of age [31, 32]. Insulin resistance in KK
miceprecedestheonsetofobesity[33].TheKKmousestrain
was modiﬁed to develop the KKAy mouse by transferring
the lethal yellow obese gene (Ay); the KKAy mouse is widely
used for obesity and diabetes research in the testing of
experimental therapies [34].
2.1.3. Rat Models of Obesity
Zucker Fatty Rat (ZFR). In 1961, L. M. Zucker and T. F.
Zucker reported a seminal ﬁnding in obesity research [35]:
an autosomal recessive mutation in the fatty (fa)g e n eo n
chromosome 5. These rats are characterized by hyperphagia
and early-onset obesity, which appears at 5 weeks of age as
an accumulation of subcutaneous fat. Although ZFR also
exhibits marked insulin resistance [36], their blood sugar
levels remain normal [37]. Later, the fa gene was shown to
be the leptin receptor gene [38]. A ZFR does not develop
diabetes [37]. However, a substrain of the ZFR that exhibits
frank diabetes was discovered and was designated the Zucker
diabetic fatty (ZDF) rats [39].
Wistar Fatty Rat. In 1981, Ikeda et al. reported another
obesity rat model, the Wistar fatty rat (WFR) [40]. The
WFR strain was derived by transferring the fa gene from
ZFR (13 M strain) to Wistar Kyoto rats, which exhibit poor
glucose tolerance [40]. WFR displays obesity from 3 weeks
after birth and develops obesity-related diseases such as type
2 diabetes, hyperinsulinemia, and hyperlipidemia. Metabolic
abnormalities are prominent in WFR males, but not in
WFR females, which display only mild insulin resistance and
some glucose intolerance [40]. The appearance of diabetes in
WFR but not in ZFR, despite the presence of the fa (leptin
receptor) mutation in both strains, could be explained by the
presence of other genetic factors in WFR. The WFR strain
is widely used for research in type 2 diabetes because aged
WFR displays diabetic complications such as nephropathy
and neuropathy [41–44].
Otsuka Long Evans Tokushima Fatty (OLETF) Rat. OLETF
rats, established by Otsuka Pharmaceuticals in Tokushima,
Japan, were developed by the selection of spontaneously type
2 diabetic rats from the outbreeding of Long Evans rats in a
closed colony of Charles River [45]. OLETF rats are hyper-
phagic beginning several weeks after birth, with increasing
body weight eventually progressing to frank obesity [46].
At approximately 25 weeks after birth, all male OLETF rats
display diabetes, as determined by oral glucose tolerance test,
whereas only 30% of female OLETF rats develop diabetes
even after 60 weeks of age. Hyperinsulinemia is observed
beginningat8weeksofage,andinsulinresistanceisobserved
beginning at 12 weeks of age. At 25 weeks of age, male
OLETF rats display hyperplasia of pancreatic islets, but islets
become atrophic by 60 weeks of age [46, 47]. In contrast to
ZDF rats, hyper-free fatty acidemia has not been observed
in OLETF rats. Instead, hypertriglyceridemia is found to
precede the onset of hyperglycemia and insulin resistance
[47]. OLETF rats are widely used in obesity and diabetes
research.
2.1.4. Diet-Induced Obesity
High-Fat Diet. A high-fat diet (HFD) is often utilized in
obesity research as a non-leptin-deﬁcient model. There are
mouse strain-speciﬁc diﬀerences in responses to the HFD
(Table 1)[48].Amongthevariousstrains,C57BL/6Jmiceare
the most widely used for HFD-induced obesity because they
exhibit abnormalities similar to human metabolic syndrome
when fed the HFD [49]. Interestingly, within the C57 mouse
strain, there are signiﬁcant diﬀerences among substrains in
response to the HFD. For instance, whereas C57BL/6J mice
exhibit HFD-induced obesity, hyperinsulinemia, and insulin
resistance that closely parallel the progression of human
disease, C57BL/KsJ mice display a weak phenotype [49].
Beside C57BL/J6 mice, sand mice and spiny mice are also
used in obesity/type 2 diabetes research. Sprague Dawley or
Long Evans rats are also used for nonmouse rodent models
of HFD-induced obesity [50].
Using such high-fat diet-induced obesity mice models,
some clues to ﬁght against human obesity have been
reported; manipulation of diet may rescue the obesity
phenotype even in high-fat-fed condition.
Watanabe et al. reported seminal ﬁnding about the
antiobesitogenic role of bile acids (BAs) in mice. BAs have
been long recognized as simple lipid solubilizers, however,
during the last decades researchers revealed that BAs play
pivotalrolesinthecomplexmetabolicregulations.Watanabe
et al. found that high-fat diet supplemented with 0.5% cholic
acid, the BA found in the largest amount, prevented weight
gain and adiposity without alteration in the amount of
food intake [51]. They found that BAs activate G-protein-
coupledTGR5receptorandinducetype 2deiodinase activity.
Such activation of type 2 deiodinase results in the conversion
of thyroxine (T4) to triiodothyronine (T3), which enhances
energy expenditure [51]. Furthermore, agonistic compound
for TGR5, INT-777, mimics such metabolic eﬀect of BAs
and inhibited the onset of steatosis in high-fat-fed mice
[52]. Furthermore, INT-777 induces incretin eﬀects via the
secretion of glucagon-like peptide (GLP)-1 and therefore
amelioratedglucosetolerance[52].Theseresearchesrevealed4 Journal of Biomedicine and Biotechnology
the potential importance of BAs for the prevention of diet-
induced obesity and associated health problem. Interestingly
postcholecystectomized patients have been shown to have
high prevalence of type 2 diabetes [53].
Another nutritional intervention method, which could
prevent metabolic abnormality, is the diet with high keto-
genic essential amino acid (KAA) such as leucine, isoleucine,
valine, lysine, and threonine. Zhang et al. have reported
that high-leucine feeding in mice prevented high-fat diet-
inducedobesity[54].Suchenhancedadministrationofhigh-
KAA mixture diet modulated lipid synthetic pathway and
prevented hepatic steatosis and insulin resistance with the
reduction of body weight under the high-fat diet [55].
Interestingly such high-KAA mixture has been shown to
improve insulin sensitivity in elderly type 2 diabetic subjects
[56]. These reports indicated that the high-fat diet-induced
obesity animals could be the good model for the experimen-
tal therapy and the translational research to discover a novel
therapeutic strategy for obesity epidemic.
2.2. Nonrodent Models of Obesity
Obese Monkeys. During evolution, primates diverged from
rodent lineages about 65–85 million years ago [57]. In
comparison, humans and other great apes (Hominoidea)
diverged from Old World monkeys (Cercopithecoidea) a
relatively recent 25 million years ago [58]. Obesity models
in Old World monkeys, such as macaques, rhesus mon-
key, and baboons, would therefore provide information
relevant to human obesity. When raised in indoor cages,
Rhesus monkeys exhibit increased rates of obesity, with
some of them developing obesity-associated diseases [59–
61]. Captive macaques display obesity in an age-dependent
manner when given food ad libitum [62]. Like humans, these
monkeysdevelop type 2 diabetes anddiabetic complications.
It is likely that reduced exercise increases the risk of obesity
in these monkeys [62–64]. Spontaneous obesity is also found
in wild baboons and in a pedigreed colony [65–67]a n d
occurs in free-ranging rhesus monkeys [68]. Furthermore, a
speciesofJapanesemonkey,Macacafuscata,developsobesity
without frank diabetes [69].
3.HumanDiseaseandObesityAnimalModels
Genetic models provide useful information about the biol-
ogy of obesity in humans. This does not mean, however,
that these models can provide information on how obesity
can cause other health problems. In this section, we intro-
duce several animal models for analyzing human obesity-
associated disease pathology.
3.1. Diabetes and Obesity. Type 2 diabetes is associated
with insulin resistance and is one of the most common
metabolic diseases. The incidence of type 2 diabetes has
dramatically increased in the past two decades, coinciding
with the epidemic of obesity. The pathogenesis of insulin
resistance and diabetes-associated complications remains
unclear. Research on type 2 diabetes using animal models of
obesity is therefore quite signiﬁcant.
Models of obesity with type 2 diabetes are classiﬁed
into two categories: (1) those containing a mutation in the
leptin or leptin receptor gene and (2) polygenic models.
Obese rodents, such as Zucker rats, ob/ob mice, and db/db
mice, are used as models for type 2 diabetes. Obesity in
these models is due to leptin signaling deﬁciency. These
rodent models exhibit microvascular complications similar
to humans, such as diabetic retinopathy and nephropathy,
and provide important models for testing experimental
therapeutics. However, leptin abnormalities only comprise a
minorityofobesity/diabetescasesinhumans[70–72]andare
not the same condition of type 2 diabetes that is a worldwide
epidemic.
Polygenic models of obesity with diabetes may provide
more insight to the human condition. Certain inbred strains
of mice exhibit remarkable obesity when fed on HFD,
whereas others remain lean [48, 49, 73], suggesting gene-
diet interactions. Furthermore, some of the strains exhibit
obesitywithsevereinsulinresistanceandglucoseintolerance,
whereas others are highly sensitive to insulin-mediated
glucose uptake and are resistant to the onset of diabetes
(Table 1)[50,74,75].Incontrast,somestrainsareveryprone
to type 2 diabetes but not severely obese. Those polygenic
models allow for analysis of diabetic phenotypes alone, or
the mice can be fed on HFD or crossed with another obesity
mouse model, such as ob/ob, db/db,o rAy (Table 1)[ 50, 74,
75].
3.2. Cancer and Obesity. O b e s i t yi nh u m a n si sa s s o c i a t e d
with the incidence of several cancers. Likewise, type 2
diabetes has been associated with an increased risk of cancer.
Several mechanisms have been proposed to explain the inter-
action between obesity and cancer development, including
theprevalenceoftype2diabetes,increasedinsulinresistance,
elevated levels of insulin-like growth factor 1 (IGF-1),
and increased production of sex steroid hormones and
adipocytokines [76–80]. However, clear molecular mecha-
nisms that explain obesity-associated cancer have yet to be
determined. Recently, Park et al. reported a breakthrough
observation in carcinogenesis in obesity [81]. They found
that diethylnitrosamine-induced HCC is signiﬁcantly higher
in both genetically (ob/ob) and HFD-induced (59% fat, 15%
protein, 26% carbohydrates) obese mice [81]. Furthermore,
HFD induced the growth of subcutaneously injected HCC,
suggestingthatobesityhasasystemiceﬀectontumorigenesis
[81]. With regard to the mechanisms of tumorigenesis in
obesity, they found that obesity is associated with increased
intracellular transcriptional factor STAT signaling and liver
inﬂammation [81]. This inﬂammation was demonstrated
to be essential for the tumor promoting eﬀects of obesity
becausethedepletionofsignalingbyinﬂammatorycytokines
IL-6 and TNF-α abolished the tumor promoting eﬀects of
obesity [81].
Metformin belongs to the biguanide class of antitype
2 diabetic drugs. Since the middle ages, the biguanide
Galega oﬃcinalis (goat’s rue or French lilac) has been used
to treat diabetic patients. Accumulating evidence suggests
that metformin reduces cancer incidence in type 2 dia-
betic patients. Metformin activates AMPK and inhibits theJournal of Biomedicine and Biotechnology 5
Table 1: Diﬀerent phenotypes of inbred mouse strains with diet- or genetically induced obesity (summary of references [50, 74, 75]).
Strain Characteristics Crossed with obese mice, and so forth
C57BL/6J High-fat diet-induced diabetes and obesity [119]L e p ob/ob mice exhibit obesity but not diabetes [120]
C57BLKS/J High-fat diet-induced diabetes and obesity weaker than
C57BL/6J [49] Lepob/ob mice exhibit obesity with severe diabetes [120]
DBA/2 More glucose tolerance than C57BL/6 on a high-fat diet
[121] Lepob/ob mice exhibit obesity with severe diabetes [122]
129sv Low insulin; more glucose tolerance than other strains on a
high-fat diet [123]
Homozygous for db allele db3J mice display
mild/transient hyperglycemia with marked
hyperinsulinemia and develop hypoglycemia leading to
sudden death [124]
BTBR Abdominal obesity with peripheral, but not hepatic insulin
resistance [125] Lepob/ob mice exhibit obesity with severe diabetes [126]
A/J Low glucose level even on a high-fat diet; obesity and
diabetes-resistant [119, 127, 128] Not reported
BALB/c Similar to A/J; glucose tolerance [121] Lepob/ob mice exhibit reduced adiposity and increased
thermogenesis and are fertile [129]
C3H High glucose tolerance with robust insulin secretion [121]N o t r e p o r t e d
AKR Sensitive to diet-induced obesity with hyperinsulinemia and
insulin resistance [48] Not reported
CAST/Ei Lean at 12 weeks on a high-fat diet [130]N o t r e p o r t e d
Nonobese Diabetic 45% fat diet-induced transient hyperglycemia with severe
obesity [75] Not reported
New Zealand Obese Resemble metabolic syndrome in humans; high-fat
diet-induced obesity and hyperglycemia [24, 25] Not reported
FVB High glucose levels with lower levels of insulin on normal
chow [75]
Leprdb/db mice display insulin resistance, severe
hyperglycemia, and marked hyperinsulinemia
compared to C57BL/6 [131]
Kuo Kondo Obesity; hyperleptinemia; increased glucose and HbA1c;
hyperinsulinemia similar to C57BLKS/J Leprdb/db mice [30]
Ay mutation in agouti results in frank diabetes with
nephropathy [34]
TallyHo Natural model of obesity with type 2 diabetes [132]N o t r e p o r t e d
Nagoya-Shibata-
Yasuda
Exhibit obesity; all males and 1/3 of females exhibit glucose
intolerance [133] Not reported
ALS/Lt Sensitive to alloxan-induced diabetes [134] Introduction of Ay mutation induces diabetes in 100%
of males and 60% of females at 24 weeks of age [135]
M16
Increased body weight, fat and food intake; both males and
females develop hyperinsulinemia; only males develop
moderate hyperglycemia [29]
Not reported
LG and SM High-fat diet-stimulated body weight gain and increased
plasma glucose more in SM than LG mice [136] Not reported
Tsumura, Suzuki,
Obese Diabetes Obesity and moderate diabetes [26, 27]N o t r e p o r t e d
Akita Mutation in insulin 2 gene; nonobese [137]N o t r e p o r t e d
mTOR signaling pathway via various mechanisms [82–
86]. Metformin treatment has been shown to result in a
gene expression proﬁle similar to that of long-term caloric
restriction [87], which can reduce the incidence of many
age-related diseases, including cancer [88, 89]. Metformin
treatment inhibits high-energy diet-stimulated colon cancer
cell growth [90] and breast tumor growth in HFD-fed mice
but did not inhibit tumor growth in mice fed normal chow
[91]. Although the eﬀects of metformin in obesity-related
cancer biology are not clear, these reports suggest that the
tumor suppressive eﬀect of metformin may involve the
amelioration of a systemic metabolic proﬁle associated with
a high-energy diet and obesity.
Elevated leptin levels, often found in obesity, may aﬀect
cancercellgrowth.Recently,Ribeiroetal.injectedandrogen-
insensitivemurineprostatecarcinomaRM1cellsintocontrol
male C57BL6 and genetic (ob/ob mice and db/db mice)
and HFD mouse models of obesity [92]. They found that
low-leptin models (ob/ob and HFD mice) exhibited large
tumors, whereas high-leptin (db/db) mice exhibited small
tumors, suggesting that leptin may inhibit RM1 tumor
growth [92]. In contrast, Gonzalez et al. reported that leptin6 Journal of Biomedicine and Biotechnology
may accelerate the growth of breast tumors in mice via
induction of VEGF-VEGFR2-mediated angiogenesis [93],
although their study used immunodeﬁcient SCID mice
and not a mouse model of obesity [94]. Similar leptin-
induced proliferation and invasiveness has been shown
in endometrial cancer [95]. Bartucci et al. reported that
colorectal cancer stem cells express leptin receptors, and
therefore leptin may induce tumor growth and interfere with
the cytotoxic eﬀects of the anticancer drug 5-FU [96]. The
reports regarding the role of leptin in carcinogenesis are still
very controversial and require further followup studies.
3.3. Obstructive Sleep Apnea and Obesity. Obstructive sleep
apnea (OSA) is an important obesity-associated health
problem that is characterized by obstruction of the airway
and depletion of oxygen tone in the blood. OSA may
be associated with the onset of hypertension, diabetes,
and coronary heart disease. Although OSA is of clinical
importance, the etiology of OSA is not yet clear, perhaps
due to the lack of appropriate animal models. The ﬁrst
animalmodelreportedtoexhibitsleepapneawastheEnglish
bulldog [97]. These animals exhibit respiration disorders
and decreased O2 saturation that worsen during rapid-eye-
movement sleep. Most bulldogs experience less than 90%
O2 saturation for prolonged durations [97]. Two varieties
of obese pigs were also found to be good models of
OSA [98, 99]. Although these models provide important
information about the pathomechanisms of OSA, large-
animal-based research is technically diﬃcult. Therefore,
for the development of experimental therapies and drugs,
rodent models are superior. In 1996, Van Lunteren et al.
reportedalteredrespiratory-associatedmusclecontractionin
genetically obese ZFR [100]. Later, this model was found to
exhibit sleep apnea syndrome [101] .Z F R sh a v es i n c eb e e n
used for various experimental therapies and have provided
important information about OSA [102–104].
Although these dog, pig, and rat models help improve
our understanding of the pathophysiology of OSA, mouse
models are critical in identifying the genes conferring disease
risk [105]. Tagaito et al. developed a gas-delivery system
that alters O2 levels depending on the sleep-wake status of
C57BL/6 male mice. However, this model is not a natural
OSA model and is not a good representation of OSA [106].
Recently, NZO mice were used as a model mouse for
sleep apnea syndrome [107]. NZO mice exhibit polygenic
obesity and metabolic syndromes, such as insulin resistance,
diabetes, hyperlipidemia, and hypertension (Table 1), much
like a human sleep apnea patient. This report suggests that
the NZO mouse may be a useful model for testing new drugs
and experimental therapies for OSA.
4.Why Do HumansGainWeight?
Why DoHumansLike toEatFat?
All the data above might be focused mainly on the
pathogenesis of obesity/obesity-related complications. Most
publications may shed light on the pathology of obesity by
forcing HFD or genetic mutations in rodents; however, the
conditions are very diﬀerent from the real problems that
humans are facing. For example, although leptin-deﬁcient
rodents have been used in many obesity-associated studies,
leptin/leptin receptor mutations are rare in humans [70–72].
The main diﬀerence between experimental animal models
and human obesity is that humans do not have induced
gene mutations and are not forced to eat HFDs. Instead,
humans tend to enjoy eating such diets. If we can answer
the question of why some individuals prefer to eat high-fat
food and others do not, we would have a direct solution for
obesity.Littleevidenceiscurrentlyavailableonthistopic,but
some seminal results have been shown [108, 109]. It has also
been reported that the variation in fat consumption (ranging
from 26 to 83% of total energy) is dependent on the response
of inbred mouse strains to the macronutrient diet selection
paradigm [110]. This theory suggests that there are strain-
speciﬁc diﬀerences in food selection behavior, which could
potentiallybemediatedbydiﬀerencesinbrainneuropeptides
[111–116]. These reports indicate that further investigation
on this topic in conjunction with human epidemiological
and genetic studies is required.
5. Conclusion
Wehavesummarizedmanycurrentanimalmodelsofobesity
and obesity-associated human diseases. However, animal
models have not yet been established for some devastat-
ing obesity-associated human diseases, including polycystic
ovary syndrome [117, 118], which is extremely prevalent
and constitutes one of the most common endocrinopathy
in women of reproductive age. Suitable animal models are
fundamental to testing novel therapeutic strategies against
disease. Therefore, intensive and continuous eﬀorts should
be made to establish novel obesity-associated animal models
that mimic human health problems.
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